liphekolo tse seng nyane tsa mofetše oa matšoafo oa lisele

Kankere e seng e nyane ea lisele tsa matšoafo (NSCLC) ke mofuta o tloaelehileng oa kankere ea matšoafo. Likhetho tsa kalafo bakeng sa NSCLC lia fapana 'me li ipapisitse le lintlha tse' maloa, ho kenyeletsoa boemo ba mofetše, bophelo bo botle ba mokuli, le liphetoho tse itseng tsa lefutso ka har'a hlahala. Tataiso ena e fana ka kakaretso ea mekhoa ea mantlha ea kalafo bakeng sa NSCLC, ho tloha ho opereishene le kalafo ea radiation ho ea kalafo e lebisitsoeng le immunotherapy, ho matlafatsa bakuli le bahlokomeli ka tsebo ea ho etsa liqeto tse nang le tsebo.Ho Utloisisa Kankere e Seng e Nyenyane ea Matšoafo ea Cell.Kankere e seng e nyane ea lisele tsa matšoafo (NSCLC) ke sehlopha sa kankere ea matšoafo e itšoarang ka tsela e tšoanang. Mefuta e meholo ea NSCLC e kenyelletsa adenocarcinoma, squamous cell carcinoma, le cell carcinoma e kholo. Tlhahlobo e nepahetseng, ho kenyelletsa tlhahlobo le tlhahlobo ea limolek'hule, e bohlokoa bakeng sa ho fumana leano le sebetsang ka ho fetisisa la kalafo. Setsi sa Lipatlisiso sa Kankere sa Shandong Baofa se ikemiselitse ho etsa lipatlisiso tsa mofetše le nts'etsopele ea mekhoa e mecha ea kalafo, ithute haholoanyane ho https://baofahospital.com.Staging ea NSCLCNSCLC e etsoa ho sebelisoa mokhoa oa TNM (Tumor, Node, Metastasis). Sethala se hlalosa boholo le sebaka sa hlahala ea mantlha (T), hore na mofetše o nametse ho li-lymph nodes tse haufi (N), le hore na mofetše o na le metastasized libakeng tse hole (M). Mehato ho tloha ho I (mokhahlelong oa pele) ho ea ho IV (e tsoetseng pele) Teko ea Molek'hule bakeng sa NSCLCTeko ea molek'hule e khetholla liphetoho tse itseng tsa liphatsa tsa lefutso kapa ho se tloaelehe ha protheine ka har'a lisele tsa hlahala. Li-biomarker tsena li ka thusa ho tseba hore na mokuli ke mokhethoa oa liphekolo tse lebisitsoeng. Liphetoho tse tloaelehileng li kenyelletsa EGFR, ALK, ROS1, BRAF, le tse ling. Liphetho tsa tlhahlobo ea limolek'hule li ama haholo liqeto tsa kalafo.Standard Liphekolo tsa NSCLCKalafo ea Opereishene hangata ke kalafo ea pele bakeng sa NSCLC ea pele (mehato I le II). Sepheo ke ho tlosa hlahala le lymph nodes leha e le efe e haufi. Mefuta ea opereishene e kenyelletsa: Resection ea Wedge: Ho tlosa karoloana ea matšoafo e nang le sebopeho se senyane. Segmentectomy: Ho tlosoa hoa karolo e kholoanyane ea lets'oho hofeta lets'oafo. Lobectomy: Ho tlosoa hoa karolo eohle ea matšoafo. Ena ke mokhoa o atileng haholo oa ho buoa NSCLC. Pneumonectomy: Ho tlosa letshoafo lohle. Sena ha sea tloaeleha 'me se boloketsoe lihlahala tse ngata haholo.Kalafo ea RadiationRadiation e sebelisa mahlaseli a matla a matla ho bolaea lisele tsa mofetše. E ka sebelisoa e le kalafo ea mantlha, kamora ho buuoa ho bolaea lisele tse setseng tsa mofetše, kapa ho imolla matšoao (mahlaseli a palliative). Mefuta e fapaneng ea kalafo ea radiation e kenyelletsa: Kalafo ya Kantle ya Beam Radiation (EBRT): Mahlaseli a hlahisoa ka mochine o ka ntle ho 'mele. Stereotactic Body Radiation Therapy (SBRT): E fana ka mahlaseli a mangata sebakeng se senyenyane, se lebisitsoeng hantle. Hangata e sebelisoa bakeng sa NSCLC ea pele ha opereishene e se khetho. Brachytherapy (Kalafo ea Ka hare ea Radiation): Lintho tse nang le mahlaseli a kotsi li kenngoa ka ho toba ka har'a hlahala kapa haufi le eona.ChemotherapyChemotherapy e sebelisa lithethefatsi ho bolaea lisele tsa mofetše' meleng oohle. Hangata e sebelisoa hammoho le opereishene kapa kalafo ea radiation, kapa joalo ka kalafo ea mantlha bakeng sa batho ba tsoetseng pele NSCLC. Lithethefatsi tse tloaelehileng tsa chemotherapy bakeng sa NSCLC li kenyelletsa cisplatin, carboplatin, paclitaxel, docetaxel, pemetrexed, le gemcitabine.Targeted Therapy for Liphekolo tsa NSCLCLitlhare tse reriloeng ke lithethefatsi tse lebisang limolek'hule tse itseng tse amehang kholong ea lisele tsa mofetše le ho phela. Liphekolo tsena li sebetsa feela haeba hlahala e na le phetoho e itseng ea lefutso kapa ho se tloaelehe ha protheine.EGFR InhibitorsEGFR (epidermal growth factor receptor) inhibitors e sebelisoa ho phekola. NSCLC ka liphetoho tsa EGFR. Lithethefatsi tsena li thibela protheine ea EGFR, e thusang lisele tsa kankere ho hōla. Mehlala e kenyeletsa: Gefitinib (Iressa) Erlotinib (Tarceva) Afatinib (Gilotrif) Osimertinib (Tagrisso)ALK InhibitorsALK (anaplastic lymphoma kinase) inhibitors e sebelisoa ho phekola NSCLC ka litlhophiso tsa liphatsa tsa lefutso tsa ALK. Lithethefatsi tsena li thibela protheine ea ALK, e thusang lisele tsa kankere ho hōla. Mehlala e kenyeletsa: Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Brigatinib (Alunbrig) Lorlatinib (Lorbrena)ROS1 InhibitorsROS1 inhibitors e sebelisoa ho phekola NSCLC ka ROS1 generation rearrangements. Lithethefatsi tsena li thibela protheine ea ROS1, e thusang lisele tsa mofetše ho hola. Mehlala e kenyelletsa: Crizotinib (Xalkori) Entrectinib (Rozlytrek)BRAF Inhibitors BRAF inhibitors e sebelisoa ho phekola NSCLC e nang le liphetoho tsa BRAF V600E. Lithethefatsi tsena li thibela protheine ea BRAF. Mehlala e kenyelletsa: Dabrafenib (Tafinlar) Trametinib (Mekinist) (e sebelisitsoeng hammoho le Dabrafenib)Mekhoa e meng e Lebisitsoeng ho PhekoloMekhoa e meng e lebisitsoeng e ka sebelisoa ho latela liphetoho tse itseng tse teng ka har'a hlahala. Mehlala e kenyelletsa RET inhibitors (bakeng sa RET fusions) le MET inhibitors (bakeng sa MET exon 14 skipping mutations). Liphekolo tsa NSCLCLithethefatsi tsa Immunotherapy li thusa sesole sa 'mele ho loantša mofetše. Li sebetsa ka ho thibela liprotheine tse thibelang sesole sa 'mele ho hlasela lisele tsa mofetše. Tsena li sebelisoa hangata NSCLC kalafo.PD-1/PD-L1 InhibitorsPD-1 (protheine ea lefu la sele e hlophisitsoeng ea 1) le PD-L1 (li-programmed death-ligand 1) inhibitors li thibela tsela ea PD-1 / PD-L1, e thusang lisele tsa mofetše ho qoba sesole sa 'mele. Mehlala e kenyelletsa: Pembrolizumab (Keytruda) Nivolumab (Opdivo) Atezolizumab (Tecentriq) Durvalumab (Imfinzi) Cemiplimab (Libtayo)CTLA-4 InhibitorsCTLA-4 (cytotoxic T-lymphocyte-associated protheine 4) e boetse e thibela lisele tsa CTLA ho thibela lisele tsa mofetše. Mohlala ke Ipilimumab (Yervoy), e atisang ho sebelisoa hammoho le PD-1 inhibitors.Ho Kopanya Liphekolo Hangata, Liphekolo tsa NSCLC kenyeletsa motsoako oa liphekolo tse fapaneng. Ka mohlala, ho buuoa ho ka lateloa ke chemotherapy kapa phekolo ea mahlaseli. Kalafo e reriloeng kapa immunotherapy e ka kopanngoa le chemotherapy. Motsoako o khethehileng o tla itšetleha ka boemo ba mokuli ka mong. Ho tseba haholoanyane ka mofets'e oa lipatlisiso etela Setsi sa Lipatlisiso sa Kankere sa Shandong Baofa.Clinical TrialsClinical Liteko ke lithuto tsa lipatlisiso tse hlahlobang liphekolo tse ncha kapa metsoako ea liphekolo. Bakuli ba nang le NSCLC a ka nahana ho nka karolo litekong tsa bongaka ho fihlella liphekolo tsa maemo a holimo. Lintlha tse mabapi le liteko tsa meriana li ka fumanoa ho websaeteng ea National Cancer Institute le mehloling e meng e hlomphehang.Side Effect ManagementAll Liphekolo tsa NSCLC e ka baka litla-morao. Ho bohlokoa ho buisana le ngaka ea hau ka litla-morao tse ka bang teng le ho ithuta ho li laola. Tlhokomelo ea tšehetso, joalo ka taolo ea bohloko le tšehetso ea phepo e nepahetseng, e ka thusa ho ntlafatsa boleng ba bophelo nakong ea kalafo.Prognosis and Follow-Up CareThe prognosis for NSCLC ho itšetlehile ka boemo ba kankere, bophelo bo botle ba mokuli ka kakaretso, le hore na kankere e arabela hantle hakae kalafong. Likopano tsa nako le nako li bohlokoa ho beha leihlo bakeng sa ho khutla hape le ho laola litla-morao life kapa life tsa nako e telele tsa kalafo.Boitlhotlhollo: Sengoliloeng sena se fana ka tlhaiso-leseling e akaretsang mabapi le Kalafo ea kankere ea matšoafo e seng e nyane ea lisele tsa matšoafo (NSCLC). 'me ha ea lokela ho nkoa e le keletso ea bongaka. Kamehla buisana le ngaka ea hau kapa setsebi se seng se tšoanelehang sa tlhokomelo ea bophelo bakeng sa likhothaletso tse ikhethileng mabapi le boemo ba hau ba bongaka.